Ozanimod Hydrochloride Patent Expiration

Ozanimod Hydrochloride is Used for treating ulcerative colitis and multiple sclerosis in adults. It was first introduced by Bristol Myers Squibb Co in its drug Zeposia on Mar 25, 2020.


Ozanimod Hydrochloride Patents

Given below is the list of patents protecting Ozanimod Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zeposia US10239846 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis Nov 15, 2030 Bristol
Zeposia US11680050 Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof Sep 30, 2038 Bristol
Zeposia US8481573 Modulators of sphingosine phosphate receptors May 14, 2029 Bristol
Zeposia US8796318 Modulators of sphingosine phosphate receptors May 14, 2029 Bristol
Zeposia US9382217 Modulators of sphingosine phosphate receptors May 14, 2029 Bristol


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳